Suppr超能文献

用于克服癌症治疗中局部治疗效果的光触发光动力纳米药物。

Light-triggered photodynamic nanomedicines for overcoming localized therapeutic efficacy in cancer treatment.

作者信息

Choi Jiwoong, Sun In-Cheol, Sook Hwang Hee, Yeol Yoon Hong, Kim Kwangmeyung

机构信息

KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea; Medicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea.

Medicinal Materials Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Republic of Korea.

出版信息

Adv Drug Deliv Rev. 2022 Jul;186:114344. doi: 10.1016/j.addr.2022.114344. Epub 2022 May 14.

Abstract

Photodynamic nanomedicines have significantly enhanced the therapeutic efficacy of photosensitizers (PSs) by overcoming critical limitations of PSs such as poor water solubility and low tumor accumulation. Furthermore, functional photodynamic nanomedicines have enabled overcoming oxygen depletion during photodynamic therapy (PDT) and tissue light penetration limitation by supplying oxygen or upconverting light in targeted tumor tissues, resulting in providing the potential to overcome biological therapeutic barriers of PDT. Nevertheless, their localized therapeutic effects still remain a huddle for the effective treatment of metastatic- or recurrent tumors. Recently, newly designed photodynamic nanomedicines and their combination chemo- or immune checkpoint inhibitor therapy enable the systemic treatment of various metastatic tumors by eliciting antitumor immune responses via immunogenic cell death (ICD). This review introduces recent advances in photodynamic nanomedicines and their applications, focusing on overcoming current limitations. Finally, the challenges and future perspectives of the clinical translation of photodynamic nanomedicines in cancer PDT are discussed.

摘要

光动力纳米药物通过克服光敏剂(PSs)的关键局限性,如水溶性差和肿瘤蓄积低等问题,显著提高了其治疗效果。此外,功能性光动力纳米药物能够通过在靶向肿瘤组织中供应氧气或上转换光来克服光动力疗法(PDT)期间的氧耗竭和组织光穿透限制,从而为克服PDT的生物治疗障碍提供了潜力。然而,它们的局部治疗效果仍然是有效治疗转移性或复发性肿瘤的一个障碍。最近,新设计的光动力纳米药物及其与化疗或免疫检查点抑制剂疗法的联合应用,能够通过免疫原性细胞死亡(ICD)引发抗肿瘤免疫反应,从而对各种转移性肿瘤进行全身治疗。本文综述了光动力纳米药物的最新进展及其应用,重点在于克服当前的局限性。最后,讨论了光动力纳米药物在癌症PDT临床转化中的挑战和未来前景。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验